Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Encouraging outcomes in older patients following nonmyeloablative haploidentical blood or marrow transplantation

ASH 2013 Annual Meeting

7 - 10 Dec 2013

Published: 7 Dec 2013

Views: 3772

Rating:

Save

Dr Yvette Kasamon - Johns Hopkins Kimmel Cancer Center, Baltimore, USA

Dr Yvette Kasamon presents the results of a recent study on blood and bone marrow transplanation at the 2013 ASH Annual Meeting.

To more fully demonstrate the utility of haploidentical bone marrow or peripheral blood stem cell transplants (haploBMT) as an alternative to fully matched transplants, this study evaluated nonmyeloablative, related haploBMT (with post-transplantation cyclophosphamide) among patients aged 50 – 75 with poor-risk haematologic malignancies.

Related Videos

SIOG 2024: Updates in haematology

Dr Ashley Rosko - The Ohio State University, Columbus, USA

SIOG 2024: Updates in haematology ( Dr Ashley Rosko - The Ohio State University, Columbus, USA )

Isatuximab plus lenalidomide and dexamethasone with bortezomib as a new standard of care for NDMM TI non-frail patients

Prof Xavier Leleu - CHU de Poitiers, Poitiers, France

Isatuximab plus lenalidomide and dexamethasone with bortezomib as a new standard of care for NDMM TI non-frail patients ( Prof Xavier Leleu - CHU de Poitiers, Poitiers, France )

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM

Dr Elias Mai - Heidelberg University, Heidelberg, Germany

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM ( Dr Elias Mai - Heidelberg University, Heidelberg, Germany )

Use of bispecifics and CAR T cells in South America

Dr Natalia Schütz - Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

Use of bispecifics and CAR T cells in South America ( Dr Natalia Schütz - Hospital Italiano de Buenos Aires, Buenos Aires, Argentina )

Treating relapsed multiple myeloma outside of use of T-cell redirected therapies

Prof Joy Ho - The University of Sydney, Sydney, Australia

Treating relapsed multiple myeloma outside of use of T-cell redirected therapies ( Prof Joy Ho - The University of Sydney, Sydney, Australia )

Guiding transplant decisions in multiple myeloma with MRD

Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA

Guiding transplant decisions in multiple myeloma with MRD ( Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA )

Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients

Prof Salomon Manier - Hospital Center University De Lille, Lille, France

Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients ( Prof Salomon Manier - Hospital Center University De Lille, Lille, France )

Choosing 1st line TKI Wisely in patients with CML

Dr Prashant Mehta - Amrita Hospirtal, Karala, India

Choosing 1st line TKI Wisely in patients with CML ( Dr Prashant Mehta - Amrita Hospirtal, Karala, India )

Status of anti BCMA therapy in myeloma

Dr Dibakar Podder - Tata Medical Center, Kolkata, India

Status of anti BCMA therapy in myeloma ( Dr Dibakar Podder - Tata Medical Center, Kolkata, India )

More from ecancer